Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
1. A method for reducing allergen-driven mucus production in the airway of a subject with allergy, the method comprising the step of administering to the subject's respiratory tract a live attenuated Bordetella pertussis strain which colonizes and replicates in the subject's respiratory tract without inducing symptoms of pertussis.
2. The method of claim 1 , wherein the live attenuated Bordetella pertussis strain is deficient in tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT).
3. The method of claim 2 , wherein the strain comprises a mutated pertussis toxin (ptx) gene, a deleted or mutated dermonecrotic (dnt) gene, and a heterologous ampG gene.
4. The method of claim 3 , wherein the heterologous ampG gene is an E. coli ampG gene that replaces the wild-type Bordetella strain ampG gene.
5. The method of claim 3 , wherein the mutation of the ptx gene comprises a substitution of an amino acid involved in substrate binding and/or an amino acid involved in catalysis.
6. The method of claim 5 , wherein the substitution of the amino acid involved in substrate binding comprises R9K and the substitution of the amino acid involved in catalysis comprises E129G.
7. The method of claim 4 , wherein the heterologous ampG gene is the only heterologous gene in the strain.
8. The method of claim 1 , wherein the live attenuated Bordetella pertussis strain is BPZE1.